{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:44:32Z","timestamp":1784389472176,"version":"3.55.0"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tremor, whether arising from neurological diseases, other conditions, or medication side effects, significantly impacts patients' lives. Treatment complexities necessitate clear algorithms and strategies. Levodopa remains pivotal for Parkinson's tremor, though response variability exists. Some dopamine agonists offer notable tremor reduction targeting D2 receptors. Propranolol effectively manages essential tremor and essential tremor plus (ET\/ET\u2009+), sometimes with primidone for added benefits, albeit dose-dependent side effects. As reserve medications anticholinergics and clozapine are used for treatment of parkinsonian tremor, 1-Octanol and certain anticonvulsant drugs for tremor of other orign, especially ET. Therapies such as invasive deep brain stimulation and lesional focused ultrasound serve for resistant cases. A medication review is crucial for all forms of tremor, but it is particularly important if medication may have triggered the tremor. Sensor-based detection and non-drug interventions like wristbands and physical therapy broaden diagnostic and therapeutic horizons, promising future tremor care enhancements. Understanding treatment nuances is a key for tailored tremor management respecting patient needs and tolerability. Successful strategies integrate pharmacological, non-invasive, and technological modalities, aiming for optimal symptom control and improved quality of life.<\/jats:p>","DOI":"10.1007\/s00702-024-02806-x","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:01:50Z","timestamp":1721786510000},"page":"1229-1246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tips and tricks in tremor treatment"],"prefix":"10.1007","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6524-0281","authenticated-orcid":false,"given":"Franziska","family":"Hopfner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Buhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Classen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Holtbernd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Koschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharias","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Paus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"4","key":"2806_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1042\/cs0690459","volume":"69","author":"B Abila","year":"1985","unstructured":"Abila B, Lazarus JH, Kingswood JC, Marshall RW, Wilson JF, Richens A (1985) Tremor: an alternative approach for investigating adrenergic mechanisms in thyrotoxicosis? Clin Sci (lond) 69(4):459\u2013463","journal-title":"Clin Sci (lond)"},{"issue":"6","key":"2806_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12(6):1937\u20131958","journal-title":"Neurol Ther"},{"issue":"Suppl 1","key":"2806_CR3","first-page":"S27","volume":"178","author":"SP Alexander","year":"2021","unstructured":"Alexander SP, Christopoulos A, Davenport AP et al (2021) The concise guide to pharmacology 2021\/22: G protein-coupled receptors. Br J Pharmacol 178(Suppl 1):S27\u2013S156","journal-title":"Br J Pharmacol"},{"key":"2806_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.parkreldis.2017.09.011","volume":"44","author":"M Alonso-Juarez","year":"2017","unstructured":"Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, Baizabal-Carvallo JF (2017) The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord 44:147\u2013150","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2806_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/toxins13010042","volume":"13","author":"C Anandan","year":"2021","unstructured":"Anandan C, Jankovic J (2021) Botulinum toxin in movement disorders: an update. Toxins (basel) 13(1):42","journal-title":"Toxins (basel)"},{"key":"2806_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.122810","volume":"456","author":"C Anandan","year":"2024","unstructured":"Anandan C, Jankovic J (2024) Botulinum toxin treatment in parkinsonism. J Neurol Sci 456:122810","journal-title":"J Neurol Sci"},{"issue":"1","key":"2806_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/acps.12171","volume":"129","author":"JH Baek","year":"2014","unstructured":"Baek JH, Kinrys G, Nierenberg AA (2014) Lithium tremor revisited: pathophysiology and treatment. Acta Psychiatr Scand 129(1):17\u201323","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"2806_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1461145705006358","volume":"10","author":"DS Baldwin","year":"2007","unstructured":"Baldwin DS, Montgomery SA, Nil R, Lader M (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10(1):73\u201384","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"2806_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/JPD-212860","volume":"12","author":"M Bartl","year":"2022","unstructured":"Bartl M, Dakna M, Schade S et al (2022) Longitudinal change and progression indicators using the movement disorder society-unified Parkinson\u2019s disease rating scale in two independent cohorts with early parkinson\u2019s disease. J Parkinsons Dis 12(1):437\u2013452","journal-title":"J Parkinsons Dis"},{"issue":"3 Suppl","key":"2806_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1017\/S031716710003780X","volume":"14","author":"M Beaulieu","year":"1987","unstructured":"Beaulieu M (1987) Clinical importance of D-1 and D-2 receptors. Can J Neurol Sci 14(3 Suppl):402\u2013406","journal-title":"Can J Neurol Sci"},{"issue":"8738","key":"2806_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0140-6736(91)91175-T","volume":"337","author":"AL Benabid","year":"1991","unstructured":"Benabid AL, Pollak P, Gervason C et al (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337(8738):403\u2013406","journal-title":"Lancet"},{"issue":"1","key":"2806_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.27121","volume":"33","author":"KP Bhatia","year":"2018","unstructured":"Bhatia KP, Bain P, Bajaj N et al (2018) Consensus Statement on the classification of tremors from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord 33(1):75\u201387","journal-title":"Mov Disord"},{"issue":"3","key":"2806_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1212\/WNL.37.3.471","volume":"37","author":"N Biary","year":"1987","unstructured":"Biary N, Koller W (1987) Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology 37(3):471\u2013474","journal-title":"Neurology"},{"issue":"8","key":"2806_CR14","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1212\/WNL.45.8.1523","volume":"45","author":"N Biary","year":"1995","unstructured":"Biary N, Bahou Y, Sofi MA, Thomas W, Al Deeb SM (1995) The effect of nimodipine on essential tremor. Neurology 45(8):1523\u20131525","journal-title":"Neurology"},{"issue":"5","key":"2806_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/02688690701552278","volume":"21","author":"P Blomstedt","year":"2007","unstructured":"Blomstedt P, Hariz GM, Hariz MI, Koskinen LO (2007) Thalamic deep brain stimulation in the treatment of essential tremor: a long-term follow-up. Br J Neurosurg 21(5):504\u2013509","journal-title":"Br J Neurosurg"},{"issue":"10","key":"2806_CR16","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/mds.22758","volume":"25","author":"P Blomstedt","year":"2010","unstructured":"Blomstedt P, Sandvik U, Tisch S (2010) Deep brain stimulation in the posterior subthalamic area in the treatment of essential tremor. Mov Disord 25(10):1350\u20131356","journal-title":"Mov Disord"},{"issue":"6","key":"2806_CR17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1212\/WNL.49.6.1587","volume":"49","author":"U Bonuccelli","year":"1997","unstructured":"Bonuccelli U, Ceravolo R, Salvetti S et al (1997) Clozapine in Parkinson\u2019s disease tremor. effects of acute and chronic administration. Neurology 49(6):1587\u20131590","journal-title":"Neurology"},{"issue":"6201","key":"2806_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/336783a0","volume":"336","author":"JR Bunzow","year":"1988","unstructured":"Bunzow JR, Van Tol HH, Grandy DK et al (1988) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336(6201):783\u2013787","journal-title":"Nature"},{"key":"2806_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003013","author":"S Burgess","year":"2001","unstructured":"Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G (2001) Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2806_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1212\/01.WNL.0000101722.95137.19","volume":"62","author":"KO Bushara","year":"2004","unstructured":"Bushara KO, Goldstein SR, Grimes GJ Jr, Burstein AH, Hallett M (2004) Pilot trial of 1-octanol in essential tremor. Neurology 62(1):122\u2013124","journal-title":"Neurology"},{"issue":"1","key":"2806_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/brain\/aww286","volume":"140","author":"H Cagnan","year":"2016","unstructured":"Cagnan H, Pedrosa D, Little S et al (2016) Stimulating at the right time: phase-specific deep brain stimulation. Brain 140(1):132\u2013145","journal-title":"Brain"},{"issue":"11","key":"2806_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: An exploratory double-blind trial. J Psychopharmacol 28(11):1088\u20131098","journal-title":"J Psychopharmacol"},{"issue":"43","key":"2806_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001809","volume":"94","author":"KH Chang","year":"2015","unstructured":"Chang KH, Wang SH, Chi CC (2015) Efficacy and safety of topiramate for essential tremor: a meta-analysis of randomized controlled trials. Medicine (baltimore) 94(43):e1809","journal-title":"Medicine (baltimore)"},{"issue":"1","key":"2806_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ana.25126","volume":"83","author":"JW Chang","year":"2018","unstructured":"Chang JW, Park CK, Lipsman N et al (2018) A prospective trial of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: results at the 2-year follow-up. Ann Neurol 83(1):107\u2013114","journal-title":"Ann Neurol"},{"issue":"5","key":"2806_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1212\/WNL.34.5.669","volume":"34","author":"ME Charness","year":"1984","unstructured":"Charness ME, Morady F, Scheinman MM (1984) Frequent neurologic toxicity associated with amiodarone therapy. Neurology 34(5):669\u2013669","journal-title":"Neurology"},{"key":"2806_CR26","first-page":"1","volume":"25","author":"S Chayasirisobhon","year":"2020","unstructured":"Chayasirisobhon S (2020) Mechanisms of action and pharmacokinetics of cannabis. Perm J 25:1\u20133","journal-title":"Perm J"},{"key":"2806_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40035-017-0086-4","volume":"6","author":"W Chen","year":"2017","unstructured":"Chen W, Hopfner F, Becktepe JS, Deuschl G (2017) Rest tremor revisited: Parkinson\u2019s disease and other disorders. Transl Neurodegener 6:16","journal-title":"Transl Neurodegener"},{"issue":"6007","key":"2806_CR28","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1126\/science.1197410","volume":"330","author":"EY Chien","year":"2010","unstructured":"Chien EY, Liu W, Zhao Q et al (2010) Structure of the human dopamine D3 receptor in complex with a D2\/D3 selective antagonist. Science 330(6007):1091\u20131095","journal-title":"Science"},{"issue":"Pt 10","key":"2806_CR29","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain 137(Pt 10):2731\u20132742","journal-title":"Brain"},{"issue":"2","key":"2806_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/WNF.0b013e3180d09969","volume":"31","author":"GS Connor","year":"2008","unstructured":"Connor GS, Edwards K, Tarsy D (2008) Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol 31(2):97\u2013103","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"2806_CR31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1212\/WNL.36.11.1543","volume":"36","author":"HA Crystal","year":"1986","unstructured":"Crystal HA (1986) Duration of effectiveness of primidone in essential tremor. Neurology 36(11):1543","journal-title":"Neurology"},{"issue":"13","key":"2806_CR32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1212\/WNL.0000000000004295","volume":"89","author":"RG Cury","year":"2017","unstructured":"Cury RG, Fraix V, Castrioto A et al (2017) Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia. Neurology 89(13):1416\u20131423","journal-title":"Neurology"},{"key":"2806_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5334\/tohm.798","volume":"13","author":"D Dai","year":"2023","unstructured":"Dai D, Fernandes J, Kim H, Coetzer H (2023) Comparative effectiveness of transcutaneous afferent patterned stimulation therapy for essential tremor: a randomized pragmatic clinical trial. Tremor Other Hyperkinet Mov (n Y) 13:38","journal-title":"Tremor Other Hyperkinet Mov (n Y)"},{"issue":"10","key":"2806_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1097\/00007611-199510000-00014","volume":"88","author":"TL Davis","year":"1995","unstructured":"Davis TL, Charles PD, Burns RS (1995) Clonazepam-sensitive intermittent dystonic tremor. South Med J 88(10):1069\u20131071","journal-title":"South Med J"},{"issue":"6","key":"2806_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5(6):525\u2013535","journal-title":"Lancet Neurol"},{"issue":"2","key":"2806_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0269881119895536","volume":"34","author":"SM de Faria","year":"2020","unstructured":"de Faria SM, de Morais FD, Tumas V et al (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson\u2019s disease. J Psychopharmacol 34(2):189\u2013196","journal-title":"J Psychopharmacol"},{"issue":"3","key":"2806_CR37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11845-011-0712-6","volume":"180","author":"U Dennison","year":"2011","unstructured":"Dennison U, Clarkson M, O\u2019Mullane J, Cassidy EM (2011) The incidence and clinical correlates of lithium toxicity: a retrospective review. I J Med Sci 180(3):661\u2013665. https:\/\/doi.org\/10.1007\/s11845-011-0712-6","journal-title":"I J Med Sci"},{"issue":"2","key":"2806_CR38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00004691-199603000-00002","volume":"13","author":"G Deuschl","year":"1996","unstructured":"Deuschl G, Krack P, Lauk M, Timmer J (1996) Clinical neurophysiology of tremor. J Clin Neurophysiol 13(2):110\u2013121","journal-title":"J Clin Neurophysiol"},{"issue":"2","key":"2806_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1474-4422(10)70322-7","volume":"10","author":"G Deuschl","year":"2011","unstructured":"Deuschl G, Raethjen J, Hellriegel H, Elble R (2011) Treatment of patients with essential tremor. Lancet Neurol 10(2):148\u2013161","journal-title":"Lancet Neurol"},{"key":"2806_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clinph.2022.01.004","volume":"136","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Becktepe JS, Dirkx M et al (2022) The clinical and electrophysiological investigation of tremor. Clin Neurophysiol 136:93\u2013129","journal-title":"Clin Neurophysiol"},{"key":"2806_CR41","unstructured":"Deuschl G, Pea S, Tremor (2022) S2k-Leitlinie in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: www.dgn.org\/leitlinien"},{"issue":"7","key":"2806_CR42","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/brain\/awx104","volume":"140","author":"L di Biase","year":"2017","unstructured":"di Biase L, Brittain JS, Shah SA et al (2017) Tremor stability index: a new tool for differential diagnosis in tremor syndromes. Brain 140(7):1977\u20131986","journal-title":"Brain"},{"issue":"3","key":"2806_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0149-2918(98)80056-8","volume":"20","author":"A Diaz-Martinez","year":"1998","unstructured":"Diaz-Martinez A, Benassinni O, Ontiveros A et al (1998) A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 20(3):467\u2013476","journal-title":"Clin Ther"},{"issue":"5","key":"2806_CR44","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3171\/2019.2.JNS183517","volume":"132","author":"M D'Souza","year":"2019","unstructured":"D\u2019Souza M, Chen KS, Rosenberg J et al (2019) Impact of skull density ratio on efficacy and safety of magnetic resonance-guided focused ultrasound treatment of essential tremor. J Neurosurg 132(5):1392\u20131397","journal-title":"J Neurosurg"},{"issue":"7","key":"2806_CR45","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1300962","volume":"369","author":"WJ Elias","year":"2013","unstructured":"Elias WJ, Huss D, Voss T et al (2013) A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med 369(7):640\u2013648","journal-title":"N Engl J Med"},{"issue":"8","key":"2806_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198529","volume":"13","author":"K Engel","year":"2018","unstructured":"Engel K, Huckhagel T, Gulberti A et al (2018) Towards unambiguous reporting of complications related to deep brain stimulation surgery: a retrospective single-center analysis and systematic review of the literature. PLoS ONE 13(8):e0198529","journal-title":"PLoS ONE"},{"issue":"3","key":"2806_CR47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/mds.26919","volume":"32","author":"AJ Espay","year":"2017","unstructured":"Espay AJ, Lang AE, Erro R et al (2017) Essential pitfalls in \u201cessential\u201d tremor. Mov Disord 32(3):325\u2013331","journal-title":"Mov Disord"},{"issue":"7","key":"2806_CR48","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"S Fahn","year":"2003","unstructured":"Fahn S, Elton RL (2003) Movement disorder society task force on rating scales for Parkinson\u2019s D The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18(7):738\u2013750","journal-title":"Mov Disord"},{"issue":"24","key":"2806_CR49","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351(24):2498\u20132508","journal-title":"N Engl J Med"},{"issue":"7","key":"2806_CR50","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/jnnp-2013-305532","volume":"85","author":"A Fasano","year":"2014","unstructured":"Fasano A, Bove F, Lang AE (2014) The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry 85(7):759\u2013769","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2806_CR51","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/mds.27700","volume":"34","author":"JJ Ferreira","year":"2019","unstructured":"Ferreira JJ, Mestre TA, Lyons KE et al (2019) MDS evidence-based review of treatments for essential tremor. Mov Disord 34(7):950\u2013958","journal-title":"Mov Disord"},{"issue":"9","key":"2806_CR52","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/jnnp.48.9.911","volume":"48","author":"LJ Findley","year":"1985","unstructured":"Findley LJ, Cleeves L, Calzetti S (1985) Primidone in essential tremor of the hands and head: a double blind controlled clinical study. J Neurol Neurosurg Psychiatry 48(9):911\u2013915","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2806_CR53","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY et al (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 33(8):1248\u20131266","journal-title":"Mov Disord"},{"issue":"4","key":"2806_CR54","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1212\/WNL.48.4.1077","volume":"48","author":"JH Friedman","year":"1997","unstructured":"Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D (1997) Benztropine versus clozapine for the treatment of tremor in Parkinson\u2019s disease. Neurology 48(4):1077\u20131081","journal-title":"Neurology"},{"issue":"Suppl 2","key":"2806_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12859-021-03961-8","volume":"22","author":"C Fuchs","year":"2021","unstructured":"Fuchs C, Nobile MS, Zamora G, Degeneffe A, Kubben P, Kaymak U (2021) Tremor assessment using smartphone sensor data and fuzzy reasoning. BMC Bioinform 22(Suppl 2):57","journal-title":"BMC Bioinform"},{"issue":"6","key":"2806_CR56","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000448926","volume":"94","author":"A Fytagoridis","year":"2016","unstructured":"Fytagoridis A, Astrom M, Samuelsson J, Blomstedt P (2016) Deep brain stimulation of the caudal zona incerta: tremor control in relation to the location of stimulation fields. Stereotact Funct Neurosurg 94(6):363\u2013370","journal-title":"Stereotact Funct Neurosurg"},{"key":"2806_CR57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40349-016-0049-8","volume":"4","author":"MN Gallay","year":"2016","unstructured":"Gallay MN, Moser D, Rossi F et al (2016) Incisionless transcranial MR-guided focused ultrasound in essential tremor: cerebellothalamic tractotomy. J Ther Ultrasound 4:5","journal-title":"J Ther Ultrasound"},{"issue":"6","key":"2806_CR58","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/1531-8249(200006)47:6<837::AID-ANA24>3.0.CO;2-2","volume":"47","author":"N Galvez-Jimenez","year":"2000","unstructured":"Galvez-Jimenez N, Hargreave M (2000) Topiramate and essential tremor. Ann Neurol 47(6):837\u2013838","journal-title":"Ann Neurol"},{"issue":"5","key":"2806_CR59","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/0306312713483678","volume":"43","author":"J Gardner","year":"2013","unstructured":"Gardner J (2013) A history of deep brain stimulation: Technological innovation and the role of clinical assessment tools. Soc Stud Sci 43(5):707\u2013728","journal-title":"Soc Stud Sci"},{"issue":"11","key":"2806_CR60","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1212\/WNL.33.11.1489","volume":"33","author":"O Gershanik","year":"1983","unstructured":"Gershanik O, Heikkila RE, Duvoisin RC (1983) Behavioral correlations of dopamine receptor activation. Neurology 33(11):1489\u20131492","journal-title":"Neurology"},{"issue":"5","key":"2806_CR61","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s004150050360","volume":"246","author":"JMM Gijtenbeek","year":"1999","unstructured":"Gijtenbeek JMM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246(5):339\u2013346","journal-title":"J Neurol"},{"key":"2806_CR62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5334\/tohm.552","volume":"10","author":"DK Gupta","year":"2020","unstructured":"Gupta DK, Marano M, Zweber C, Boyd JT, Kuo SH (2020) Prevalence and relationship of rest tremor and action tremor in Parkinson\u2019s disease. Tremor Other Hyperkinet Mov (n Y) 10:58","journal-title":"Tremor Other Hyperkinet Mov (n Y)"},{"issue":"3","key":"2806_CR63","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/00207454.2016.1181631","volume":"127","author":"SA Hamed","year":"2017","unstructured":"Hamed SA, Abdellah MM (2017) The relationship between valproate induced tremors and circulating neurotransmitters: a preliminary study. Int J Neurosci 127(3):236\u2013242","journal-title":"Int J Neurosci"},{"key":"2806_CR64","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/j.wneu.2019.01.281","volume":"126","author":"M Harary","year":"2019","unstructured":"Harary M, Segar DJ, Hayes MT, Cosgrove GR (2019) Unilateral thalamic deep brain stimulation versus focused ultrasound thalamotomy for essential tremor. World Neurosurg 126:e144\u2013e152","journal-title":"World Neurosurg"},{"issue":"1","key":"2806_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/jnnp.72.1.47","volume":"72","author":"GM Hariz","year":"2002","unstructured":"Hariz GM, Lindberg M, Bergenheim AT (2002) Impact of thalamic deep brain stimulation on disability and health-related quality of life in patients with essential tremor. J Neurol Neurosurg Psychiatry 72(1):47\u201352","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2806_CR66","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.232","author":"D Haubenberger","year":"2014","unstructured":"Haubenberger D, Nahab FB, Voller B, Hallett M (2014) Treatment of essential tremor with long-chain alcohols: still experimental or ready for prime time? Tremor Other Hyperkinet Mov (n y). https:\/\/doi.org\/10.5334\/tohm.232","journal-title":"Tremor Other Hyperkinet Mov (n y)"},{"issue":"2","key":"2806_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/1756285616679123","volume":"10","author":"P Hedera","year":"2017","unstructured":"Hedera P (2017) Emerging strategies in the management of essential tremor. Ther Adv Neurol Disord 10(2):137\u2013148","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"2806_CR68","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00002826-199406000-00007","volume":"17","author":"JM Henderson","year":"1994","unstructured":"Henderson JM, Yiannikas C, Morris JG, Einstein R, Jackson D, Byth K (1994) Postural tremor of Parkinson\u2019s disease. Clin Neuropharmacol 17(3):277\u2013285","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"2806_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41594-017-0011-7","volume":"25","author":"D Hilger","year":"2018","unstructured":"Hilger D, Masureel M, Kobilka BK (2018) Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol 25(1):4\u201312","journal-title":"Nat Struct Mol Biol"},{"key":"2806_CR70","unstructured":"H\u00f6glinger G, T Cea (2023) Parkinson-Krankheit, S2k-Leitlinie, , in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Online: www.dgn.org\/leitlinien (abgerufen am 02.02.2024)"},{"issue":"1","key":"2806_CR71","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/ene.13454","volume":"25","author":"F Hopfner","year":"2018","unstructured":"Hopfner F, Deuschl G (2018) Is essential tremor a single entity? Eur J Neurol 25(1):71\u201382","journal-title":"Eur J Neurol"},{"issue":"4","key":"2806_CR72","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s13311-020-00899-2","volume":"17","author":"F Hopfner","year":"2020","unstructured":"Hopfner F, Deuschl G (2020) Managing Essential Tremor. Neurotherapeutics 17(4):1603\u20131621","journal-title":"Neurotherapeutics"},{"issue":"8","key":"2806_CR73","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.parkreldis.2015.05.005","volume":"21","author":"F Hopfner","year":"2015","unstructured":"Hopfner F, Erhart T, Knudsen K et al (2015) Testing for alcohol sensitivity of tremor amplitude in a large cohort with essential tremor. Parkinsonism Relat Disord 21(8):848\u2013851","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2806_CR74","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(19)30400-4","volume":"19","author":"F Hopfner","year":"2020","unstructured":"Hopfner F, Hoglinger GU, Kuhlenbaumer G et al (2020) beta-adrenoreceptors and the risk of Parkinson\u2019s disease. Lancet Neurol 19(3):247\u2013254","journal-title":"Lancet Neurol"},{"issue":"3","key":"2806_CR75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/mds.870120312","volume":"12","author":"JP Hubble","year":"1997","unstructured":"Hubble JP, Busenbark KL, Wilkinson S et al (1997) Effects of thalamic deep brain stimulation based on tremor type and diagnosis. Mov Disord 12(3):337\u2013341","journal-title":"Mov Disord"},{"issue":"4","key":"2806_CR76","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/00002826-199008000-00005","volume":"13","author":"AJ Hughes","year":"1990","unstructured":"Hughes AJ, Lees AJ, Stern GM (1990) Apomorphine in the diagnosis and treatment of parkinsonian tremor. Clin Neuropharmacol 13(4):312\u2013317","journal-title":"Clin Neuropharmacol"},{"issue":"14","key":"2806_CR77","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/mds.26455","volume":"30","author":"DS Huss","year":"2015","unstructured":"Huss DS, Dallapiazza RF, Shah BB, Harrison MB, Diamond J, Elias WJ (2015) Functional assessment and quality of life in essential tremor with bilateral or unilateral DBS and focused ultrasound thalamotomy. Mov Disord 30(14):1937\u20131943","journal-title":"Mov Disord"},{"key":"2806_CR78","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5334\/tohm.59","volume":"10","author":"SH Isaacson","year":"2020","unstructured":"Isaacson SH, Peckham E, Tse W et al (2020) Prospective home-use study on non-invasive neuromodulation therapy for essential tremor. Tremor Other Hyperkinet Mov (n Y) 10:29","journal-title":"Tremor Other Hyperkinet Mov (n Y)"},{"issue":"2","key":"2806_CR79","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5414\/NPP29084","volume":"29","author":"S Ishida","year":"2010","unstructured":"Ishida S, Sugino M, Hosokawa T et al (2010) Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol 29(2):84\u201388","journal-title":"Clin Neuropathol"},{"issue":"2","key":"2806_CR80","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mds.870010204","volume":"1","author":"J Jankovic","year":"1986","unstructured":"Jankovic J, Fahn S (1986) A survey of 100 patients with tremor. Mov Disord 1(2):61\u201369. https:\/\/doi.org\/10.1002\/mds.870010204","journal-title":"Mov Disord"},{"issue":"8","key":"2806_CR81","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/WNL.41.8.1185","volume":"41","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Schwartz K (1991) Botulinum toxin treatment of tremors. Neurology 41(8):1185\u20131188","journal-title":"Neurology"},{"issue":"21","key":"2806_CR82","doi-asserted-by":"publisher","first-page":"e2020","DOI":"10.1212\/WNL.0000000000006551","volume":"91","author":"J Junker","year":"2018","unstructured":"Junker J, Brandt V, Berman BD et al (2018) Predictors of alcohol responsiveness in dystonia. Neurology 91(21):e2020\u2013e2026","journal-title":"Neurology"},{"issue":"10","key":"2806_CR83","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/j.1528-1157.2000.tb04610.x","volume":"41","author":"AM Kanner","year":"2000","unstructured":"Kanner AM, Parra J, Frey M (2000) The, \u201cforgotten\u201d cross-tolerance between phenobarbital and primidone: it can prevent acute primidone-related toxicity. Epilepsia 41(10):1310\u20131314","journal-title":"Epilepsia"},{"key":"2806_CR84","doi-asserted-by":"publisher","first-page":"2050313X1984297","DOI":"10.1177\/2050313X19842976","volume":"7","author":"M Kishimoto","year":"2019","unstructured":"Kishimoto M, Adachi M, Takahashi K, Washizaki K (2019) Clonazepam-induced liver dysfunction, severe hyperlipidaemia, and hyperglycaemic crisis: a case report. SAGE Open Med Case Rep 7:2050313X19842976","journal-title":"SAGE Open Med Case Rep"},{"issue":"7","key":"2806_CR85","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.clinph.2021.01.031","volume":"132","author":"U Kleinholdermann","year":"2021","unstructured":"Kleinholdermann U, Wullstein M, Pedrosa D (2021) Prediction of motor Unified Parkinson\u2019s disease rating scale scores in patients with Parkinson\u2019s disease using surface electromyography. Clin Neurophysiol 132(7):1708\u20131713","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"2806_CR86","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.neurom.2022.09.010","volume":"26","author":"U Kleinholdermann","year":"2023","unstructured":"Kleinholdermann U, Bacara B, Timmermann L, Pedrosa DJ (2023) Prediction of movement ratings and deep brain stimulation parameters in idiopathic Parkinson\u2019s Disease. Neuromodulation 26(2):356\u2013363","journal-title":"Neuromodulation"},{"issue":"12","key":"2806_CR87","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1002\/mds.23846","volume":"26","author":"K Knudsen","year":"2011","unstructured":"Knudsen K, Lorenz D, Deuschl G (2011) A clinical test for the alcohol sensitivity of essential tremor. Mov Disord 26(12):2291\u20132295","journal-title":"Mov Disord"},{"issue":"2","key":"2806_CR88","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/archneur.1986.00520020020009","volume":"43","author":"WC Koller","year":"1986","unstructured":"Koller WC (1986) Pharmacologic treatment of parkinsonian tremor. Arch Neurol 43(2):126\u2013127","journal-title":"Arch Neurol"},{"issue":"1","key":"2806_CR89","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1212\/WNL.36.1.121","volume":"36","author":"WC Koller","year":"1986","unstructured":"Koller WC, Royse VL (1986) Efficacy of primidone in essential tremor. Neurology 36(1):121\u2013124","journal-title":"Neurology"},{"issue":"12","key":"2806_CR90","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1212\/WNL.39.12.1587","volume":"39","author":"WC Koller","year":"1989","unstructured":"Koller WC, Vetere-Overfield B (1989) Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 39(12):1587\u20131588","journal-title":"Neurology"},{"issue":"6","key":"2806_CR91","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mds.870130608","volume":"13","author":"P Krack","year":"1998","unstructured":"Krack P, Benazzouz A, Pollak P et al (1998) Treatment of tremor in Parkinson\u2019s disease by subthalamic nucleus stimulation. Mov Disord 13(6):907\u2013914","journal-title":"Mov Disord"},{"issue":"9","key":"2806_CR92","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/mds.26693","volume":"31","author":"KJ Kubota","year":"2016","unstructured":"Kubota KJ, Chen JA, Little MA (2016) Machine learning for large-scale wearable sensor data in Parkinson\u2019s disease: concepts, promises, pitfalls, and futures. Mov Disord 31(9):1314\u20131326","journal-title":"Mov Disord"},{"issue":"6","key":"2806_CR93","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1124\/mol.55.6.1011","volume":"55","author":"Y Kurata","year":"1999","unstructured":"Kurata Y, Marszalec W, Yeh JZ, Narahashi T (1999) Agonist and potentiation actions of n-octanol on gamma-aminobutyric acid type A receptors. Mol Pharmacol 55(6):1011\u20131019","journal-title":"Mol Pharmacol"},{"key":"2806_CR94","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5334\/tohm.672","volume":"11","author":"A Lenka","year":"2021","unstructured":"Lenka A, Louis ED (2021) Primidone intolerance in essential tremor: is it more than just age? Tremor Other Hyperkinet Mov (n Y) 11:57","journal-title":"Tremor Other Hyperkinet Mov (n Y)"},{"key":"2806_CR95","unstructured":"Lenkapothula N, Cascella M. Primidone. StatPearls (2024) Treasure Island (FL) ineligible companies. Disclosure: Marco Cascella declares no relevant financial relationships with ineligible companies"},{"issue":"4","key":"2806_CR96","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jvoice.2021.03.026","volume":"37","author":"RA Lester-Smith","year":"2023","unstructured":"Lester-Smith RA, Miller CH, Cherney LR (2023) Behavioral therapy for tremor or dystonia affecting voice in speakers with hyperkinetic dysarthria: a systematic review. J Voice 37(4):561\u2013573","journal-title":"J Voice"},{"issue":"1","key":"2806_CR97","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41531-022-00414-8","volume":"8","author":"WS Lim","year":"2022","unstructured":"Lim WS, Chiu S-I, Wu M-C et al (2022) An integrated biometric voice and facial features for early detection of Parkinson\u2019s disease. Npj Parkinson\u2019s Disease 8(1):145","journal-title":"Npj Parkinson's Disease"},{"issue":"8","key":"2806_CR98","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mds.20884","volume":"21","author":"D Lorenz","year":"2006","unstructured":"Lorenz D, Schwieger D, Moises H, Deuschl G (2006) Quality of life and personality in essential tremor patients. Mov Disord 21(8):1114\u20131118","journal-title":"Mov Disord"},{"key":"2806_CR99","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/B978-0-323-98817-9.00012-0","volume":"196","author":"ED Louis","year":"2023","unstructured":"Louis ED (2023) Essential tremor. Handb Clin Neurol 196:389\u2013401","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"2806_CR100","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/mds.22838","volume":"25","author":"ED Louis","year":"2010","unstructured":"Louis ED, Ferreira JJ (2010) How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 25(5):534\u2013541","journal-title":"Mov Disord"},{"issue":"8","key":"2806_CR101","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/archneur.57.8.1194","volume":"57","author":"ED Louis","year":"2000","unstructured":"Louis ED, Ford B, Barnes LF (2000) Clinical subtypes of essential tremor. Arch Neurol 57(8):1194\u20131198","journal-title":"Arch Neurol"},{"key":"2806_CR102","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.parkreldis.2019.06.017","volume":"65","author":"L Luo","year":"2019","unstructured":"Luo L, Andrews H, Alcalay RN et al (2019) Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord 65:178\u2013183","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"2806_CR103","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/mds.29154","volume":"37","author":"S Luo","year":"2022","unstructured":"Luo S, Zou H, Stebbins GT et al (2022) Dissecting the domains of Parkinson\u2019s disease: insights from longitudinal item response theory modeling. Mov Disord 37(9):1904\u20131914","journal-title":"Mov Disord"},{"issue":"12","key":"2806_CR104","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/crj.13711","volume":"17","author":"LH Ma","year":"2023","unstructured":"Ma LH, Jia L, Bai L (2023) Safety outcomes of salbutamol: A systematic review and meta-analysis. Clin Respir J 17(12):1254\u20131264","journal-title":"Clin Respir J"},{"issue":"Pt 7","key":"2806_CR105","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1093\/brain\/aww109","volume":"139","author":"M Masellis","year":"2016","unstructured":"Masellis M, Collinson S, Freeman N et al (2016) Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study. Brain 139(Pt 7):2050\u20132062","journal-title":"Brain"},{"issue":"1","key":"2806_CR106","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/acn3.51943","volume":"11","author":"P McGurrin","year":"2024","unstructured":"McGurrin P, Norato G, Thompson-Westra J et al (2024) Objective response to ethanol in essential tremor: results from a standardized ethanol challenge study. Ann Clin Transl Neurol 11(1):156\u2013168","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2806_CR107","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ncl.2014.09.011","volume":"33","author":"SH Mehta","year":"2015","unstructured":"Mehta SH, Morgan JC, Sethi KD (2015) Drug-induced movement disorders. Neurol Clin 33(1):153\u2013174","journal-title":"Neurol Clin"},{"issue":"10","key":"2806_CR108","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/mds.99","volume":"33","author":"Y Meng","year":"2018","unstructured":"Meng Y, Solomon B, Boutet A et al (2018) Magnetic resonance-guided focused ultrasound thalamotomy for treatment of essential tremor: a 2-year outcome study. Mov Disord 33(10):1647\u20131650","journal-title":"Mov Disord"},{"issue":"2","key":"2806_CR109","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","volume":"128","author":"MJ Millan","year":"2010","unstructured":"Millan MJ (2010) From the cell to the clinic: a comparative review of the partial D(2)\/D(3)receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson\u2019s disease. Pharmacol Ther 128(2):229\u2013273","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2806_CR110","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1124\/jpet.102.039867","volume":"303","author":"MJ Millan","year":"2002","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. a multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303(2):791\u2013804","journal-title":"J Pharmacol Exp Ther"},{"key":"2806_CR111","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.parkreldis.2019.01.023","volume":"63","author":"SO Mittal","year":"2019","unstructured":"Mittal SO, Lenka A, Jankovic J (2019) Botulinum toxin for the treatment of tremor. Parkinsonism Relat Disord 63:31\u201341","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"2806_CR112","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/bios11040099","volume":"11","author":"J Mo","year":"2021","unstructured":"Mo J, Priefer R (2021) Medical devices for tremor suppression: current status and future directions. Biosensors (basel) 11(4):99","journal-title":"Biosensors (basel)"},{"issue":"2","key":"2806_CR113","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.3171\/2017.11.FOCUS17628","volume":"44","author":"N Mohammed","year":"2018","unstructured":"Mohammed N, Patra D, Nanda A (2018) A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor. Neurosurg Focus 44(2):E4","journal-title":"Neurosurg Focus"},{"issue":"12","key":"2806_CR114","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S1474-4422(05)70250-7","volume":"4","author":"JC Morgan","year":"2005","unstructured":"Morgan JC, Sethi KD (2005) Drug-induced tremors. Lancet Neurol 4(12):866\u2013876","journal-title":"Lancet Neurol"},{"issue":"14","key":"2806_CR115","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/mds.23240","volume":"25","author":"G Mostile","year":"2010","unstructured":"Mostile G, Jankovic J (2010) Alcohol in essential tremor and other movement disorders. Mov Disord 25(14):2274\u20132284","journal-title":"Mov Disord"},{"issue":"4","key":"2806_CR116","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s13311-011-0045-1","volume":"8","author":"FB Nahab","year":"2011","unstructured":"Nahab FB, Wittevrongel L, Ippolito D et al (2011) An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. Neurotherapeutics 8(4):753\u2013762","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2806_CR117","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/jpet.102.039883","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi A, Cussac D, Quentric Y et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. agonist and antagonist properties at Serotonin, 5-HT<sub>1<\/sub> and 5-HT<sub>2<\/sub>, receptor subtypes. J Pharmacol Exp Ther 303(2):815\u2013822","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2806_CR118","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1124\/jpet.102.039875","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi A, Cussac D, Audinot V et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic RECEPTOR II agonist and antagonist properties at subtypes of dopamine D2-like receptor and \u03b1<sub>1<\/sub>\/\u03b1<sub>2<\/sub>-Adrenoceptor. J Pharmacol Exp Ther 303(2):805\u2013814","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"2806_CR119","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMct1208070","volume":"367","author":"MS Okun","year":"2012","unstructured":"Okun MS (2012) Deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 367(16):1529\u20131538","journal-title":"N Engl J Med"},{"issue":"2","key":"2806_CR120","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13(2):141\u2013149","journal-title":"Lancet Neurol"},{"issue":"10","key":"2806_CR121","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/mds.28726","volume":"36","author":"CW Olanow","year":"2021","unstructured":"Olanow CW, Poewe W, Rascol O, Stocchi F (2021) On-Demand therapy for OFF episodes in Parkinson\u2019s disease. Mov Disord 36(10):2244\u20132253","journal-title":"Mov Disord"},{"key":"2806_CR122","first-page":"317","volume-title":"International Review of Neurobiology","author":"W Ondo","year":"2022","unstructured":"Ondo W (2022) Chapter eleven - enhancing GABA inhibition is the next generation of medications for essential tremor. In: Kuo S-H, Louis ED (eds) International Review of Neurobiology. Academic Press, pp 317\u2013334"},{"issue":"1","key":"2806_CR123","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mdc3.12560","volume":"5","author":"W Ondo","year":"2018","unstructured":"Ondo W, Hashem V, LeWitt PA et al (2018) Comparison of the fahn-tolosa-marin clinical rating scale and the essential tremor rating assessment scale. Mov Disord Clin Pract 5(1):60\u201365","journal-title":"Mov Disord Clin Pract"},{"issue":"7","key":"2806_CR124","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archneurol.2009.96","volume":"66","author":"CF Orr","year":"2009","unstructured":"Orr CF, Ahlskog JE (2009) Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 66(7):865\u2013869","journal-title":"Arch Neurol"},{"issue":"2","key":"2806_CR125","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mds.10083","volume":"17","author":"P O'Suilleabhain","year":"2002","unstructured":"O\u2019Suilleabhain P, Dewey RB Jr (2002) Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord 17(2):382\u2013386","journal-title":"Mov Disord"},{"issue":"2","key":"2806_CR126","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","volume":"23","author":"SS O'Sullivan","year":"2009","unstructured":"O\u2019Sullivan SS, Evans AH, Lees AJ (2009) Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 23(2):157\u2013170","journal-title":"CNS Drugs"},{"issue":"4","key":"2806_CR127","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.21724","volume":"23","author":"EJ Pappert","year":"2008","unstructured":"Pappert EJ, Germanson T, Myobloc\/Neurobloc European Cervical Dystonia Study G (2008) Botulinum toxin type B vs type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord 23(4):510\u2013517","journal-title":"Mov Disord"},{"issue":"5","key":"2806_CR128","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mds.27637","volume":"34","author":"YS Park","year":"2019","unstructured":"Park YS, Jung NY, Na YC, Chang JW (2019) Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. Mov Disord 34(5):727\u2013734","journal-title":"Mov Disord"},{"issue":"12","key":"2806_CR129","doi-asserted-by":"publisher","first-page":"e1378","DOI":"10.1212\/WNL.0000000000007134","volume":"92","author":"S Paschen","year":"2019","unstructured":"Paschen S, Forstenpointner J, Becktepe J et al (2019) Long-term efficacy of deep brain stimulation for essential tremor: An observer-blinded study. Neurology 92(12):e1378\u2013e1386","journal-title":"Neurology"},{"issue":"24","key":"2806_CR130","first-page":"3047","volume":"51","author":"C Pfeiffer","year":"1994","unstructured":"Pfeiffer C, Wagner ML (1994) Clozapine therapy for Parkinson\u2019s disease and other movement disorders. Am J Hosp Pharm 51(24):3047\u20133053","journal-title":"Am J Hosp Pharm"},{"issue":"2","key":"2806_CR131","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JPD-225060","volume":"13","author":"W Pirker","year":"2023","unstructured":"Pirker W, Katzenschlager R, Hallett M, Poewe W (2023) Pharmacological treatment of tremor in Parkinson\u2019s disease revisited. J Parkinsons Dis 13(2):127\u2013144","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2806_CR132","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp.70.1.78","volume":"70","author":"J Raethjen","year":"2001","unstructured":"Raethjen J, Lemke MR, Lindemann M, Wenzelburger R, Krack P, Deuschl G (2001) Amitriptyline enhances the central component of physiological tremor. J Neurol Neurosurg Psychiatry 70(1):78\u201382","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2806_CR133","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4137\/JCNSD.S13570","volume":"6","author":"AH Rajput","year":"2014","unstructured":"Rajput AH, Rajput A (2014) Medical treatment of essential tremor. J Cent Nerv Syst Dis 6:29\u201339","journal-title":"J Cent Nerv Syst Dis"},{"issue":"8","key":"2806_CR134","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/mds.26997","volume":"32","author":"VK Ravikumar","year":"2017","unstructured":"Ravikumar VK, Parker JJ, Hornbeck TS et al (2017) Cost-effectiveness of focused ultrasound, radiosurgery, and DBS for essential tremor. Mov Disord 32(8):1165\u20131173","journal-title":"Mov Disord"},{"key":"2806_CR135","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.parkreldis.2021.01.001","volume":"83","author":"S Santos de Alencar","year":"2021","unstructured":"Santos de Alencar S, Crippa JAS, Brito MCM, Pimentel AV, Cecilio Hallak JE, Tumas V (2021) A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. Parkinsonism Relat Disord 83:37\u201340","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2806_CR136","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/mdc3.13154","volume":"8","author":"S Sasikumar","year":"2021","unstructured":"Sasikumar S, Matta R, Munhoz RP et al (2021) Advanced therapies for the management of dopamine dysregulation syndrome in Parkinson\u2019s disease. Mov Disord Clin Pract 8(3):400\u2013405","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"2806_CR137","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00002826-199002000-00007","volume":"13","author":"E Sasso","year":"1990","unstructured":"Sasso E, Perucca E, Fava R, Calzetti S (1990) Primidone in the long-term treatment of essential tremor: a prospective study with computerized quantitative analysis. Clin Neuropharmacol 13(1):67\u201376","journal-title":"Clin Neuropharmacol"},{"issue":"14","key":"2806_CR138","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003795","volume":"88","author":"SR Schreglmann","year":"2017","unstructured":"Schreglmann SR, Bauer R, Hagele-Link S et al (2017) Unilateral cerebellothalamic tract ablation in essential tremor by MRI-guided focused ultrasound. Neurology 88(14):1329\u20131333","journal-title":"Neurology"},{"key":"2806_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120208","volume":"435","author":"P Schwingenschuh","year":"2022","unstructured":"Schwingenschuh P, Espay AJ (2022) Functional tremor. J Neurol Sci 435:120208","journal-title":"J Neurol Sci"},{"issue":"4","key":"2806_CR140","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"Seeman P (2015) Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69(4):183\u2013189","journal-title":"Synapse"},{"issue":"2","key":"2806_CR141","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M et al (2019) Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review. Mov Disord 34(2):180\u2013198","journal-title":"Mov Disord"},{"issue":"5","key":"2806_CR142","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S1353-8020(01)00043-8","volume":"8","author":"M Serrano-Duenas","year":"2002","unstructured":"Serrano-Duenas M (2002) Fluoxetine-induced tremor: clinical features in 21 patients. Parkinsonism Relat Disord 8(5):325\u2013327","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2806_CR143","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1353-8020(03)00070-1","volume":"10","author":"M Serrano-Duenas","year":"2003","unstructured":"Serrano-Duenas M (2003) Use of primidone in low doses (250 mg\/day) versus high doses (750 mg\/day) in the management of essential tremor. double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord 10(1):29\u201333","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2806_CR144","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1176\/jnp.2.1.64","volume":"2","author":"KD Sethi","year":"1990","unstructured":"Sethi KD, Zamrini EY (1990) Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci 2(1):64\u201366","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2806_CR145","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5334\/tohm.682","volume":"12","author":"C Shah","year":"2022","unstructured":"Shah C, Jackson GR, Sarwar AI, Mandava P, Jamal F (2022) Treatment patterns in essential tremor: a retrospective analysis. Tremor Other Hyperkinet Mov (n Y) 12:10","journal-title":"Tremor Other Hyperkinet Mov (n Y)"},{"issue":"2","key":"2806_CR146","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10072-022-06420-1","volume":"44","author":"M Shahien","year":"2023","unstructured":"Shahien M, Elaraby A, Gamal M et al (2023) Physical therapy interventions for the management of hand tremors in patients with Parkinson\u2019s disease: a systematic review. Neurol Sci 44(2):461\u2013470","journal-title":"Neurol Sci"},{"issue":"4","key":"2806_CR147","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s13246-018-0696-x","volume":"41","author":"Y Shahsavar","year":"2018","unstructured":"Shahsavar Y, Ghoshuni M, Talaei A (2018) Quantifying clinical improvements in patients with depression under the treatment of transcranial direct current stimulation using event related potentials. Australas Phys Eng Sci Med 41(4):973\u2013983","journal-title":"Australas Phys Eng Sci Med"},{"issue":"1132","key":"2806_CR148","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/postgradmedj-2019-136647","volume":"96","author":"S Sharma","year":"2019","unstructured":"Sharma S, Pandey S (2019) Treatment of essential tremor: current status. Postgrad Med J 96(1132):84\u201393","journal-title":"Postgrad Med J"},{"issue":"9","key":"2806_CR149","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1111\/bcp.14777","volume":"87","author":"Y Sheng","year":"2021","unstructured":"Sheng Y, Zhou X, Yang S, Ma P, Chen C (2021) Modelling item scores of unified Parkinson\u2019s disease rating scale part III for greater trial efficiency. Br J Clin Pharmacol 87(9):3608\u20133618","journal-title":"Br J Clin Pharmacol"},{"issue":"19","key":"2806_CR150","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A et al (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19):1699\u20131706","journal-title":"Neurology"},{"issue":"10","key":"2806_CR151","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1001\/archinte.1986.00360220252041","volume":"146","author":"RA Sirota","year":"1986","unstructured":"Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M (1986) Metoclopramide-induced parkinsonism in hemodialysis patients. report of two cases. Arch Intern Med 146(10):2070\u20132071","journal-title":"Arch Intern Med"},{"issue":"3","key":"2806_CR152","first-page":"198","volume":"35","author":"SC Smith","year":"2014","unstructured":"Smith SC, Wagner MS (2014) Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 35(3):198\u2013201","journal-title":"Neuro Endocrinol Lett"},{"issue":"3","key":"2806_CR153","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF02333855","volume":"11","author":"G Tedeschi","year":"1990","unstructured":"Tedeschi G, Sasso E, Marshall RW, Bonavita V (1990) Tremor in Parkinson disease: acute response to oral levodopa. Ital J Neurol Sci 11(3):259\u2013263","journal-title":"Ital J Neurol Sci"},{"issue":"4","key":"2806_CR154","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ana.21716","volume":"66","author":"RB Tinsley","year":"2009","unstructured":"Tinsley RB, Bye CR, Parish CL et al (2009) Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol 66(4):472\u2013484","journal-title":"Ann Neurol"},{"issue":"9","key":"2806_CR155","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00702-022-02498-1","volume":"129","author":"L Tonges","year":"2022","unstructured":"Tonges L, Buhmann C, Klebe S et al (2022) Blood-based biomarker in Parkinson\u2019s disease: potential for future applications in clinical research and practice. J Neural Transm (vienna) 129(9):1201\u20131217","journal-title":"J Neural Transm (vienna)"},{"issue":"10","key":"2806_CR156","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1212\/WNL.0000000000008875","volume":"94","author":"T Tsuboi","year":"2020","unstructured":"Tsuboi T, Jabarkheel Z, Zeilman PR et al (2020) Longitudinal follow-up with VIM thalamic deep brain stimulation for dystonic or essential tremor. Neurology 94(10):e1073\u2013e1084","journal-title":"Neurology"},{"issue":"8","key":"2806_CR157","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/jnnp-2019-322676","volume":"91","author":"J van de Wardt","year":"2020","unstructured":"van de Wardt J, van der Stouwe AM, Dirkx M et al (2020) Systematic clinical approach for diagnosing upper limb tremor. J Neurol Neurosurgamp Psychiatry 91(8):822\u2013830","journal-title":"J Neurol Neurosurgamp Psychiatry"},{"issue":"3","key":"2806_CR158","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00213-011-2340-2","volume":"218","author":"M van Holstein","year":"2011","unstructured":"van Holstein M, Aarts E, van der Schaaf ME et al (2011) Human cognitive flexibility depends on dopamine D2 receptor signaling. Psychopharmacology 218(3):567\u2013578","journal-title":"Psychopharmacology"},{"issue":"2","key":"2806_CR159","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3171\/jns.1972.36.2.0184","volume":"36","author":"FC Velasco","year":"1972","unstructured":"Velasco FC, Molina-Negro P, Bertrand C, Hardy J (1972) Further definition of the subthalamic target for arrest of tremor. J Neurosurg 36(2):184\u2013191","journal-title":"J Neurosurg"},{"key":"2806_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.680011","volume":"12","author":"B Vescio","year":"2021","unstructured":"Vescio B, Quattrone A, Nistico R, Crasa M, Quattrone A (2021) Wearable devices for assessment of tremor. Front Neurol 12:680011","journal-title":"Front Neurol"},{"issue":"4","key":"2806_CR161","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1172\/JCI83621","volume":"126","author":"B Voller","year":"2016","unstructured":"Voller B, Lines E, McCrossin G et al (2016) Dose-escalation study of octanoic acid in patients with essential tremor. J Clin Invest 126(4):1451\u20131457","journal-title":"J Clin Invest"},{"issue":"1","key":"2806_CR162","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0304-3940(01)01971-1","volume":"308","author":"J Wang","year":"2001","unstructured":"Wang J, Liu ZL, Chen B (2001) Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson\u2019s disease. Neurosci Lett 308(1):21\u201324","journal-title":"Neurosci Lett"},{"issue":"6361","key":"2806_CR163","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1126\/science.aan5468","volume":"358","author":"S Wang","year":"2017","unstructured":"Wang S, Wacker D, Levit A et al (2017) D(4) dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358(6361):381\u2013386","journal-title":"Science"},{"issue":"7695","key":"2806_CR164","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature25758","volume":"555","author":"S Wang","year":"2018","unstructured":"Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL (2018) Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 555(7695):269\u2013273","journal-title":"Nature"},{"issue":"5","key":"2806_CR165","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S1474-4422(19)30397-7","volume":"19","author":"E Warmerdam","year":"2020","unstructured":"Warmerdam E, Hausdorff JM, Atrsaei A et al (2020) Long-term unsupervised mobility assessment in movement disorders. Lancet Neurol 19(5):462\u2013470","journal-title":"Lancet Neurol"},{"issue":"1","key":"2806_CR166","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM, Follett K, Stern M et al (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301(1):63\u201373","journal-title":"JAMA"},{"key":"2806_CR167","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.parkreldis.2017.03.017","volume":"40","author":"RE Wharen Jr","year":"2017","unstructured":"Wharen RE Jr, Okun MS, Guthrie BL et al (2017) Thalamic DBS with a constant-current device in essential tremor: a controlled clinical trial. Parkinsonism Relat Disord 40:18\u201326","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"2806_CR168","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/ana.410350422","volume":"35","author":"EF Wijdicks","year":"1994","unstructured":"Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA (1994) FK506-induced neurotoxicity in liver transplantation. Ann Neurol 35(4):498\u2013501","journal-title":"Ann Neurol"},{"issue":"6","key":"2806_CR169","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1474-4422(10)70093-4","volume":"9","author":"A Williams","year":"2010","unstructured":"Williams A, Gill S, Varma T et al (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson\u2019s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9(6):581\u2013591","journal-title":"Lancet Neurol"},{"issue":"17","key":"2806_CR170","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1021\/acschemneuro.0c00332","volume":"11","author":"SM Wilson","year":"2020","unstructured":"Wilson SM, Wurst MG, Whatley MF, Daniels RN (2020) Classics in chemical neuroscience: pramipexole. ACS Chem Neurosci 11(17):2506\u20132512","journal-title":"ACS Chem Neurosci"},{"key":"2806_CR171","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2018.08.017","volume":"58","author":"JK Wong","year":"2019","unstructured":"Wong JK, Cauraugh JH, Ho KWD et al (2019) STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 58:56\u201362","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2806_CR172","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mdc3.12266","volume":"3","author":"TK Yaw","year":"2016","unstructured":"Yaw TK, Fox SH, Lang AE (2016) Clozapine in Parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action. Mov Disord Clin Pract 3(2):116\u2013124","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"2806_CR173","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3171\/2016.10.JNS16758","volume":"128","author":"M Zaaroor","year":"2018","unstructured":"Zaaroor M, Sinai A, Goldsher D, Eran A, Nassar M, Schlesinger I (2018) Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson\u2019s disease and essential tremor cases. J Neurosurg 128(1):202\u2013210","journal-title":"J Neurosurg"},{"issue":"3","key":"2806_CR174","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/cns.12670","volume":"23","author":"H Zach","year":"2017","unstructured":"Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC (2017) Cognitive stress reduces the effect of levodopa on Parkinson\u2019s resting tremor. CNS Neurosci Ther 23(3):209\u2013215","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"2806_CR175","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/jnnp.2006.100222","volume":"78","author":"C Zadikoff","year":"2007","unstructured":"Zadikoff C, Munhoz RP, Asante AN et al (2007) Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 78(2):147\u2013151","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"19","key":"2806_CR176","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1212\/WNL.0b013e318236f0fd","volume":"77","author":"TA Zesiewicz","year":"2011","unstructured":"Zesiewicz TA, Elble RJ, Louis ED et al (2011) Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 77(19):1752\u20131755","journal-title":"Neurology"},{"issue":"4","key":"2806_CR177","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11940-013-0239-4","volume":"15","author":"TA Zesiewicz","year":"2013","unstructured":"Zesiewicz TA, Shaw JD, Allison KG, Staffetti JS, Okun MS, Sullivan KL (2013) Update on treatment of essential tremor. Curr Treat Options Neurol 15(4):410\u2013423","journal-title":"Curr Treat Options Neurol"},{"key":"2806_CR178","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.576579","volume":"11","author":"CQ Zhang","year":"2020","unstructured":"Zhang CQ, He BM, Hu ML, Sun HB (2020) Risk of valproic acid-related tremor: a systematic review and meta-analysis. Front Neurol 11:576579","journal-title":"Front Neurol"},{"issue":"10","key":"2806_CR179","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/psp4.12853","volume":"11","author":"H Zou","year":"2022","unstructured":"Zou H, Aggarwal V, Stebbins GT et al (2022) Application of longitudinal item response theory models to modeling Parkinson\u2019s disease progression. CPT Pharm Syst Pharmacol 11(10):1382\u20131392","journal-title":"CPT Pharm Syst Pharmacol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-024-02806-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-024-02806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T16:05:38Z","timestamp":1729267538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-024-02806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":179,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2806"],"URL":"https:\/\/doi.org\/10.1007\/s00702-024-02806-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Franziska Hopfner is funded by the DFG, the Erwin R\u00f6ver Stiftung and the CurePSP Foundation and receives author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers. Carsten Buhmann received royalties from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and fees for lectures and\/or honour boards from AbbVie, Bial, Desitin, Kyowa Kirin, Merz, STADA Pharma, TAD Pharma, UCB, and Zambon. Stephan Klebe received honoraria for lectures from Esteve Pharma, Ipsen, AbbVie, Roche, Stadapharm and Bial. Joseph Classen receives or has received funding from DFG, BMBF, royalties from Thieme medical publishers and W. Kohlhammer GmbH medical publishers; honoraria for lectures from AbbVie, Bayer, BIAL, Biogen, Desitin Arzneimittel GmbH, Roche, UCB Pharma, Zambon. David Pedrosa is funded by the European Commission, EITHEalth and the Reinfried Pohl-Stiftung. David Pedrosa received honoraria as a speaker at symposia sponsored by Bial, Boston Scientific Corp., Medtronic, AbbVie Inc., Zambon, and Esteve Pharmaceuticals GmbH. He received payments as a consultant for Boston Scientific Corp and Bayer, and he was awarded a scientific scholarship from Boston Scientific Corp. for a project titled \"Sensor-based optimization of Deep Brain Stimulation settings in Parkinson's disease\". David Pedrosa had his travel expenses reimbursed by Esteve Pharmaceuticals GmbH and Boston Scientific Corp for attending conferences. Florian Holtbernd has received funding from the DFG and the RWTH Aachen University. He has received travel and conference fees from Abbvie, Bial, Desitin, Abbott, and Zambon. Jiri Koschel has received travel and conference fees from Desitin, Bial Medronic and Zambon. Zacharias Kohl received honoraria for lectures from AbbVie, BIAL, Pfizer, Desitin Arzneimittel GmbH, Stadapharm and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}